跳至主要内容
临床试验/ITMCTR1900002601
ITMCTR1900002601已完成3 期

Efficacy and Safety of the Chinese Herbal Formula Granules in Chronic Kidney Disease Stage 3: A Prospective, Multi-center, Randomized, Placebo-controlled, Double-blind Clinical Trial

Affiliated Hospital of Nanjing University of Chinese Medicine0 个研究点开始时间: 待定最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional study

入排标准

年龄范围
18 至 75(—)
性别
All

入选标准

  • Male and female patients diagnosed as primary CKD aged 18-75 years with estimated glomerular filtration rate (eGFR) >= 30 ml/min/1.73m2 and < 60 ml/min/1.73m2 calculated with the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation and 24-hour proteinuria <=2.0 g/d. Blood pressure was managed <=130/80 mmHg.

排除标准

  • Patients with acute kidney injury, polycystic kidney disease, secondary kidney disease such as diabetic nephropathy were not recruited. Patients were receiving glucocorticoids, immunosuppressants and Tripterygium drug were excluded. Patients with concurrent serious disease, including primary cardiac, cerebral, pulmonary, hepatic, hematological, psychiatric disease, and pregnancy or lactation were also not included.

研究者

发起方
Affiliated Hospital of Nanjing University of Chinese Medicine

相似试验